Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk

Abstract
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited.
Funding Information
  • Medtronic (Funded the ONYX ONE Trial)

This publication has 19 references indexed in Scilit: